MicroRNA‑320a is downregulated in non‑small cell lung cancer and suppresses tumor cell growth and invasion by directly targeting insulin‑like growth factor 1 receptor

Wang,Jianguo; Shi,Chunyun; Wang,Jianfei; Cao,Li; Zhong,Li; Wang,Dongmei

doi:10.3892/ol.2017.5863

MicroRNA‑320a is downregulated in non‑small cell lung cancer and suppresses tumor cell growth and invasion by directly targeting insulin‑like growth factor 1 receptor

Authors:
- Jianguo Wang
- Chunyun Shi
- Jianfei Wang
- Li Cao
- Li Zhong
- Dongmei Wang
View Affiliations

Affiliations: College of Life Sciences, Agricultural University of Hebei, Baoding, Hebei 071001, P.R. China, Department of Pediatrics, Baoding Children's Hospital, Baoding, Hebei 071000, P.R. China, College of Life Sciences, Hebei University, Baoding, Hebei 071000, P.R. China
Published online on: March 14, 2017 https://doi.org/10.3892/ol.2017.5863
Pages: 3247-3252

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulating evidence has demonstrated that microRNAs (miRs/miRNAs) are implicated in carcinogenesis and cancer progression, and can function as oncogenes or tumor suppressor genes in human cancer types. Previous profile studies of miRNA expression levels have revealed that miR‑320a was downregulated in breast cancer, colon cancer, bladder cancer, glioblastoma and salivary adenoid cystic carcinoma. However, its expression level, potential functions and the mechanisms underlying its functions in non‑small cell lung cancer (NSCLC) require further investigation. The present study investigated the expression level, biological roles and underlying molecular mechanisms of miR‑320a in NSCLC. The expression levels of miR‑320a in NSCLC tissue and cell lines were detected using the reverse transcription‑quantitative polymerase chain reaction. Cell proliferation and Transwell invasion assays were performed to examine the effects of miR‑320a on NSCLC cells. In addition, bioinformatic analysis, western blot analysis and luciferase reporter assays were performed to identify the direct gene target of miR‑320a in NSCLC. In the present study it was demonstrated that miR‑320a was significantly downregulated in NSCLC tissues and cell lines. Ectopic overexpression of miR‑320a suppressed the proliferation and invasion of NSCLC cells. Further studies indicated that miR‑320a directly targeted the 3'‑untranslated region of insulin‑like growth factor 1 receptor (IGF‑1R) and suppressed its expression at the mRNA and protein levels. As well as restoring the miR‑320a expression level, the knockdown of IGF‑1R also decreased the growth and invasion of the NSCLC cells. These results suggested that miR‑320a served as a tumor suppressor in the NSCLC cells by directly targeting IGF‑1R. Therefore, miR‑320a should be investigated as a therapeutic target for the treatment of NSCLC.

View Figures

View References

1	Shi WY, Liu KD, Xu SG, Zhang JT, Yu LL, Xu KQ and Zhang TF: Gene expression analysis of lung cancer. Eur Rev Med Pharmacol Sci. 18:217–228. 2014.PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Boffetta P and Nyberg F: Contribution of environmental factors to cancer risk. Br Med Bull. 68:71–94. 2003. View Article : Google Scholar : PubMed/NCBI
4	Didkowska J, Manczuk M, McNeill A, Powles J and Zatonski W: Lung cancer mortality at ages 35–54 in the European Union: Ecological study of evolving tobacco epidemics. BMJ. 331:189–191. 2005. View Article : Google Scholar : PubMed/NCBI
5	Ridge CA, McErlean AM and Ginsberg MS: Epidemiology of lung cancer. Semin Intervent Radiol. 30:93–98. 2013. View Article : Google Scholar : PubMed/NCBI
6	Paliogiannis P, Attene F, Cossu A, Budroni M, Cesaraccio R, Tanda F, Trignano M and Palmieri G: Lung cancer epidemiology in North Sardinia, Italy. Multidiscip Respir Med. 8:452013. View Article : Google Scholar : PubMed/NCBI
7	Zhang B, Liu T, Wu T, Wang Z, Rao Z and Gao J: microRNA-137 functions as a tumor suppressor in human non-small cell lung cancer by targeting SLC22A18. Int J Biol Macromol. 74:111–118. 2015. View Article : Google Scholar : PubMed/NCBI
8	Youlden DR, Cramb SM and Baade PD: The International Epidemiology of lung cancer: Geographical distribution and secular trends. J Thorac Oncol. 3:819–831. 2008. View Article : Google Scholar : PubMed/NCBI
9	Yoda S, Soejima K, Hamamoto J, Yasuda H, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Naoki K and Betsuyaku T: Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer. Lung Cancer. 85:366–372. 2014. View Article : Google Scholar : PubMed/NCBI
10	de Sanchez Cos J, Sojo Gonzélez MA, Montero MV, Pérez Calvo MC, Vicente MJ and Valle MH: Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer. 63:140–145. 2009. View Article : Google Scholar : PubMed/NCBI
11	Crino L, Weder W, van Meerbeeck J and Felip E: ESMO Guidelines Working Group: Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21:(Suppl 5). v103–v115. 2010. View Article : Google Scholar : PubMed/NCBI
12	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
13	Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB: Prediction of mammalian microRNA targets. Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
14	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
15	Broderick JA and Zamore PD: MicroRNA therapeutics. Gene Ther. 18:1104–1110. 2011. View Article : Google Scholar : PubMed/NCBI
16	Yu G, Jia Z and Dou Z: miR-24-3p regulates bladder cancer cell proliferation, migration, invasion and autophagy by targeting DEDD. Oncol Rep. 37:1123–1131. 2017.PubMed/NCBI
17	Zu C, Liu T and Zhang G: MicroRNA-506 inhibits malignancy of colorectal carcinoma cells by targeting LAMC1. Ann Clin Lab Sci. 46:666–674. 2016.PubMed/NCBI
18	Bao J, Zou JH, Li CY and Zheng GQ: miR-194 inhibits gastric cancer cell proliferation and tumorigenesis by targeting KDM5B. Eur Rev Med Pharmacol Sci. 20:4487–4493. 2016.PubMed/NCBI
19	Qi Z, Cai S, Cai J, Chen L, Yao Y, Chen L and Mao Y: miR-491 regulates glioma cells proliferation by targeting TRIM28 in vitro. BMC Neurol. 16:2482016. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
22	Heist RS: First-line systemic therapy for non-small cell lung cancer. Hematol Oncol Clin North Am. 31:59–70. 2017. View Article : Google Scholar : PubMed/NCBI
23	Ge H, Li B, Hu WX, Li RJ, Jin H, Gao MM and Ding CM: MicroRNA-148b is down-regulated in non-small cell lung cancer and associated with poor survival. Int J Clin Exp Pathol. 8:800–805. 2015.PubMed/NCBI
24	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
25	Mishra PJ and Merlino G: MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest. 119:2119–2123. 2009.PubMed/NCBI
26	Wang B, Yang Z, Wang H, Cao Z, Zhao Y, Gong C, Ma L, Wang X, Hu X and Chen S: MicroRNA-320a inhibits proliferation and invasion of breast cancer cells by targeting RAB11A. Am J Cancer Res. 5:2719–2729. 2015. View Article : Google Scholar : PubMed/NCBI
27	Yang H, Yu J, Wang L, Ding D, Zhang L, Chu C, Chen Q, Xu Z, Zou Q and Liu X: miR-320a is an independent prognostic biomarker for invasive breast cancer. Oncol Lett. 8:1043–1050. 2014.PubMed/NCBI
28	Sun JY, Huang Y, Li JP, Zhang X, Wang L, Meng YL, Yan B, Bian YQ, Zhao J, Wang WZ, et al: MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting β-catenin. Biochem Biophys Res Commun. 420:787–792. 2012. View Article : Google Scholar : PubMed/NCBI
29	Shang C, Zhang H, Guo Y, Hong Y, Liu Y and Xue Y: MiR-320a down-regulation mediates bladder carcinoma invasion by targeting ITGB3. Mol Biol Rep. 41:2521–2527. 2014. View Article : Google Scholar : PubMed/NCBI
30	Guo T, Feng Y, Liu Q, Yang X, Jiang T, Chen Y and Zhang Q: MicroRNA-320a suppresses in GBM patients and modulates glioma cell functions by targeting IGF-1R. Tumour Biol. 35:11269–11275. 2014. View Article : Google Scholar : PubMed/NCBI
31	Sun L, Liu B, Lin Z, Yao Y, Chen Y, Li Y, Chen J, Yu D, Tang Z, Wang B, et al: MiR-320a acts as a prognostic factor and inhibits metastasis of salivary adenoid cystic carcinoma by targeting ITGB3. Mol Cancer. 14:962015. View Article : Google Scholar : PubMed/NCBI
32	Zhang Y, He X, Liu Y, Ye Y, Zhang H, He P, Zhang Q, Dong L, Liu Y and Dong J: microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. Oncol Rep. 27:685–694. 2012.PubMed/NCBI
33	Lu M, Ding K, Zhang G, Yin M, Yao G, Tian H, Lian J, Liu L, Liang M, Zhu T and Sun F: MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ. Sci Rep. 5:87352015. View Article : Google Scholar : PubMed/NCBI
34	Xishan Z, Ziying L, Jing D and Gang L: MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia. Sci Rep. 5:124602015. View Article : Google Scholar : PubMed/NCBI
35	Qi X, Li J, Zhou C, Lv C and Tian M: MicroRNA-320a inhibits cell proliferation, migration and invasion by targeting BMI-1 in nasopharyngeal carcinoma. FEBS Lett. 588:3732–3738. 2014. View Article : Google Scholar : PubMed/NCBI
36	Werner H and LeRoith D: The role of the insulin-like growth factor system in human cancer. Adv Cancer Res. 68:183–223. 1996. View Article : Google Scholar : PubMed/NCBI
37	Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer. 12:159–169. 2012.PubMed/NCBI